Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
PURPOSE: Identification of prognostic factors in patients with malignant pleural mesothelioma based on prospectively collected international data. PATIENTS AND METHODS: From October 1984 to October 1993, 204 eligible adult patients with malignant pleural mesothelioma were entered into five consecutive prospective European Organization for Research and Treatment of Cancer (EORTC) phase II clinical trials designed to assess the efficacy of various anticancer drugs (mitoxantrone, epidoxorubicin, etoposide, and paclitaxel). The Cox model was used to assess 13 factors related to biology and disease history with respect to survival. RESULTS: The median survival duration was 12.6 months from diagnosis and 8.4 months from trial entry. In the multivariate analysis, poor prognosis was associated with a poor performance status, a high WBC count, a probable/possible histologic diagnosis of mesothelioma, male gender, and having sarcomatous tissue as the histologic subtype. Taking these five factors into consideration, patients were classified into two groups: a good-prognosis group (1-year survival rate, 40%; 95% confidence interval [CI], 30% to 50%) and a poor-prognosis group (1-year survival, 12%; 95% CI, 4% to 20%). CONCLUSION: These results may help to design new clinical trials in pleural mesothelioma by selecting more homogenous groups of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Harrison's Principles of Internal Medicine.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,514
Linear Statistical Inference and its Applications: Second Editon
Rao, C. R. (1973) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316436 · Cited by 10,489
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Albain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1618 · Cited by 728
Statistical aspects of prognostic factor studies in oncology
Simon, R., & Altman, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.192 · Cited by 582
Regression models for prognostic prediction: advantages, problems, and suggested solutions.
Fe, H., Kl, L., Matchar, D. B., & Ta, R. (1985) · PubMed · Cited by 559
Mossman, B. T., & Gee, J. B. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906293202604 · Cited by 497
Diffuse Malignant Mesothelioma: Prospective Evaluation of 69 Patients
CHAHINIAN, A. P., PAJAK, T. F., HOLLAND, J. F., NORTON, L., AMBINDER, R. M., & MANDEL, E. M. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-6-746 · Cited by 354
Cited by
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Robinson, B. W., Musk, A. W., & Lake, R. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67025-0 · Cited by 664
Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., Dienemann, H., Galateau-Salle, F., Hennequin, C., Hillerdal, G., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00063109 · Cited by 638
Self-citationHusain, Colby, Ordóñez, Allen, Attanoos, Beasley, Butnor, Chirieac, Churg, Dacic, et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0124-ra · Cited by 619
van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., Legrand, C., Bottomley, A., Debruyne, C., & Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.20005.14.589 · Cited by 617
Self-citationMalignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
Ross, P. J., Ashley, S., Norton, A., Priest, K., Waters, J. S., Eisen, T., Smith, I. E., & O'Brien, M. E. R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601781 · Cited by 476
Clive, A. O., Kahan, B. C., Hooper, C. E., Bhatnagar, R., Morley, A. J., Zahan-Evans, N., Bintcliffe, O. J., Boshuizen, R. C., Fysh, E. T. H., Tobin, C. L., et al. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205285 · Cited by 446
Maio, M., Scherpereel, A., Calabrò, L., Aerts, J., Perez, S. C., Bearz, A., Nackaerts, K., Fennell, D. A., Kowalski, D., Tsao, A. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30446-1 · Cited by 424
Calabrò, L., Morra, A., Fonsatti, E., Cutaia, O., Amato, G., Giannarelli, D., Di Giacomo, A. M., Danielli, R., Altomonte, M., Mutti, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70381-4 · Cited by 356
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335
Weder, W., Stahel, R. A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., Lardinois, D., Betticher, D., Schmid, R., Stupp, R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm093 · Cited by 320
ERS/EACTS statement on the management of malignant pleural effusions
Bibby, A. C., Dorn, P., Psallidas, I., Porcel, J. M., Janssen, J., Froudarakis, M., Subotic, D., Astoul, P., Licht, P., Schmid, R., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00349-2018 · Cited by 316
Kao, S. C. H., Pavlakis, N., Harvie, R., Vardy, J. L., Boyer, M. J., van Zandwijk, N., & Clarke, S. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2245 · Cited by 316
Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
Ceresoli, G. L., Zucali, P. A., Favaretto, A. G., Grossi, F., Bidoli, P., Del Conte, G., Ceribelli, A., Bearz, A., Morenghi, E., Cavina, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3190 · Cited by 296
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
Self-citationPopat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., Roy, A., Gilligan, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.009 · Cited by 271
“73 (0) 50 (1) 33 (3) 17 (3) 11 (5) 6 (7) 3 (9) Median PFS (95% CI) 6-month PFS% (95% CI)”
Kindler, H. L., Karrison, T. G., Gandara, D. R., Lu, C., Krug, L. M., Stevenson, J. P., Jänne, P. A., Quinn, D. I., Koczywas, M. N., Brahmer, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5869 · Cited by 257
Kidd, A. C., McGettrick, M., Tsim, S., Halligan, D. L., Bylesjo, M., & Blyth, K. G. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2017-000240 · Cited by 206
“Our models also closely resemble the two best validated MPM prognostic scores, the CALGB score(7) and the EORTC score.(8) The concordance of our results, which are based on unselected registry data analysed using Lasso regression, with these studies, which involved highly selected clinical trial populations and were a…”
MethodResultMeyerhoff, R. R., Yang, C.-F. J., Speicher, P. J., Gulack, B. C., Hartwig, M. G., D'Amico, T. A., Harpole, D. H., & Berry, M. F. (2015) · Journal of Surgical Research · doi:10.1016/j.jss.2015.01.043 · Cited by 199
Kadota, K., Suzuki, K., Colovos, C., Sima, C. S., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.146 · Cited by 168
Ceresoli, G. L., Aerts, J. G., Dziadziuszko, R., Ramlau, R., Cedres, S., van Meerbeeck, J. P., Mencoboni, M., Planchard, D., Chella, A., Crinò, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30532-7 · Cited by 164
Brims, F. J. H., Meniawy, T. M., Duffus, I., de Fonseka, D., Segal, A., Creaney, J., Maskell, N., Lake, R. A., de Klerk, N., & Nowak, A. K. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.108 · Cited by 160
Diagnosis and Prognosis-Review of Biomarkers for Mesothelioma
Sun, H. H., Vaynblat, A., & Pass, H. I. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.60 · Cited by 55
An epigenetic mechanism for capecitabine resistance in mesothelioma
Kosuri, K. V., Wu, X., Wang, L., Villalona-Calero, M. A., & Otterson, G. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.095 · Cited by 44
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
“demonstrated that sarcomatoid sub-type, as well as poor performance status, high white blood count and male gender, are associated with poor prognosis [9].”
Background(2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.11.15 · Cited by 24
Expression analysis of HMGB 1 in histological samples of malignant pleural mesothelioma
Rrapaj, E., Trisolini, E., Bertero, L., Salvo, M., Indellicato, R., Andorno, S., Garcia‐Manteiga, J. M., Rena, O., & Boldorini, R. L. (2018) · Histopathology · doi:10.1111/his.13470 · Cited by 17
Metadata
- Authors
- Curran, D., Sahmoud, T., Therasse, P., van Meerbeeck, J., Postmus, P. E., & Giaccone, G.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-01
- Volume
- 16
- Issue
- 1
- Pages
- 145-152
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2101834873
- Cited by
- 543
- References
- 34
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.